Autonomix Medical Inc. announced new subgroup clinical data from its proof-of-concept study, which was presented at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium. The data demonstrated rapid, durable, and clinically meaningful pain relief in pancreatic cancer patients across all disease stages, from Stage 2 through Stage 4, including those with limited treatment options. The findings were shared during Poster Session B under the title "Pain mitigation in pancreatic adenocarcinoma: A long-term analysis of denervation via transvascular RF energy-based ablation" by Dr. Robert S. Schwartz, Chief Medical Officer of Autonomix Medical. The dataset included patients with severe pancreatic cancer-related pain, and the subgroup analysis expanded upon previously reported results from the company’s ongoing clinical evaluation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autonomix Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9622676-en) on January 09, 2026, and is solely responsible for the information contained therein.